Der sås en forbigående stigning i serumkreatinin inden for 10 dage hos 1, 8% af patienterne behandlet med Aclasta mod 0, 8% hos patienterne behandlet med placebo.
There was a transient increase in serum creatinine observed within 10 days in 1.8% of Aclasta-treated patients versus 0.8% of placebo-treated patients.